FY2025 Earnings Forecast for Waters Issued By KeyCorp

Waters Co. (NYSE:WAT) – Equities researchers at KeyCorp issued their FY2025 earnings per share estimates for shares of Waters in a research note issued on Monday, March 31st. KeyCorp analyst P. Knight forecasts that the medical instruments supplier will post earnings of $12.76 per share for the year. KeyCorp has a “Overweight” rating and a $460.00 price objective on the stock. The consensus estimate for Waters’ current full-year earnings is $12.86 per share.

Other equities research analysts have also issued reports about the company. Bank of America reduced their price target on Waters from $430.00 to $410.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Scotiabank upgraded shares of Waters from a “sector perform” rating to a “sector outperform” rating and increased their price target for the stock from $430.00 to $450.00 in a research note on Thursday, February 13th. StockNews.com lowered shares of Waters from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. increased their target price on shares of Waters from $380.00 to $390.00 and gave the stock a “neutral” rating in a research report on Thursday, March 6th. Finally, Robert W. Baird raised Waters from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $396.00 to $407.00 in a research report on Wednesday, March 26th. Ten equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $401.31.

Waters Price Performance

WAT opened at $362.21 on Wednesday. The stock has a fifty day moving average price of $384.62 and a 200 day moving average price of $373.38. The company has a current ratio of 0.94, a quick ratio of 0.65 and a debt-to-equity ratio of 1.14. Waters has a 1 year low of $279.24 and a 1 year high of $423.56. The stock has a market cap of $21.52 billion, a price-to-earnings ratio of 33.82, a PEG ratio of 3.79 and a beta of 1.00.

Waters (NYSE:WAT) last released its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, beating the consensus estimate of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%.

Hedge Funds Weigh In On Waters

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lederer & Associates Investment Counsel CA grew its holdings in shares of Waters by 1.0% during the 1st quarter. Lederer & Associates Investment Counsel CA now owns 3,155 shares of the medical instruments supplier’s stock worth $1,163,000 after purchasing an additional 30 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Waters by 15.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,318 shares of the medical instruments supplier’s stock worth $1,602,000 after purchasing an additional 593 shares during the period. Siemens Fonds Invest GmbH boosted its stake in Waters by 8,167.6% during the fourth quarter. Siemens Fonds Invest GmbH now owns 51,590 shares of the medical instruments supplier’s stock worth $19,139,000 after buying an additional 50,966 shares in the last quarter. Menard Financial Group LLC bought a new stake in Waters in the 4th quarter valued at $128,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Waters in the 4th quarter valued at $22,948,000. 94.01% of the stock is currently owned by institutional investors.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.